Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Breast Cancer knowledge, perceptions and practices in a rural Community in Coastal Kenya.

Sayed S, Ngugi AK, Mahoney MR, Kurji J, Talib ZM, Macfarlane SB, Wynn TA, Saleh M, Lakhani A, Nderitu E, Agoi F, Premji Z, Zujewski JA, Moloo Z.

BMC Public Health. 2019 Feb 12;19(1):180. doi: 10.1186/s12889-019-6464-3.

2.

Knowledge Summaries for Comprehensive Breast Cancer Control: Feedback From Target Audiences in Kenya.

Cira MK, Zujewski JA, Dvaladze A, Brand NR, Vogel AL.

J Glob Oncol. 2019 Jan;5:1-6. doi: 10.1200/JGO.18.00119.

3.

Building a Network of Health Professionals for Breast and Cervical Cancer Control in the Andean Region.

Mendoza-Cervantes D, Otero I, Zujewski JA, Ferrandiz Salazar J, López Córdova G, Muha C, Stevens L.

J Glob Oncol. 2018 Sep;4:1-8. doi: 10.1200/JGO.2016.008714. Epub 2017 Jun 12.

4.

Knowledge Summaries for Comprehensive Breast Cancer Control.

Zujewski JA, Dvaladze AL, Ilbawi A, Anderson BO, Luciani S, Stevens L, Torode J.

J Glob Oncol. 2018 Sep;4:1-7. doi: 10.1200/JGO.17.00141. Epub 2017 Nov 16. Review.

5.

Sentinel Lymph Node Biopsy Pathology and 2-Year Postsurgical Recurrence of Breast Cancer in Kenyan Women.

Brand NR, Wasike R, Makhdomi K, Chauhan R, Moloo Z, Gakinya SM, Neugut AI, Zujewski JA, Sayed S.

J Glob Oncol. 2018 Sep;4:1-7. doi: 10.1200/JGO.17.00111. Epub 2017 Dec 7.

6.

National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.

Seidman AD, Bordeleau L, Fehrenbacher L, Barlow WE, Perlmutter J, Rubinstein L, Wedam SB, Hershman DL, Hayes JF, Butler LP, Smith ML, Regan MM, Beaver JA, Amiri-Kordestani L, Rastogi P, Zujewski JA, Korde LA.

J Clin Oncol. 2018 Sep 13:JCO1800242. doi: 10.1200/JCO.18.00242. [Epub ahead of print]

PMID:
30212295
7.

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.

Spraggs CF, Parham LR, Briley LP, Warren L, Williams LS, Fraser DJ, Jiang Z, Aziz Z, Ahmed S, Demetriou G, Mehta A, Jackson N, Byrne J, Andersson M, Toi M, Harris L, Gralow J, Zujewski JA, Crescenzo R, Armour A, Perez E, Piccart M.

Pharmacogenomics J. 2018 May 22;18(3):480-486. doi: 10.1038/tpj.2017.39. Epub 2017 Aug 8.

PMID:
28786423
8.

CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data.

Zujewski JA, Rubinstein L.

NPJ Breast Cancer. 2017 Jul 20;3:27. doi: 10.1038/s41523-017-0029-3. eCollection 2017. Review.

9.

Exploring stigma as a barrier to cancer service engagement with breast cancer survivors in Kampala, Uganda.

Meacham E, Orem J, Nakigudde G, Zujewski JA, Rao D.

Psychooncology. 2016 Oct;25(10):1206-1211. doi: 10.1002/pon.4215. Epub 2016 Aug 21.

PMID:
27421234
10.

Breast Camps for Awareness and Early Diagnosis of Breast Cancer in Countries With Limited Resources: A Multidisciplinary Model From Kenya.

Sayed S, Moloo Z, Ngugi A, Allidina A, Ndumia R, Mutuiri A, Wasike R, Wahome C, Abdihakin M, Kasmani R, Spears CD, Oigara R, Mwachiro EB, Busarla SV, Kibor K, Ahmed A, Wawire J, Sherman O, Saleh M, Zujewski JA, Dawsey SM.

Oncologist. 2016 Sep;21(9):1138-48. doi: 10.1634/theoncologist.2016-0004. Epub 2016 Jul 8.

11.

Changing Paradigms in Breast Cancer Therapeutics: An Extended Abstract.

Zujewski JA.

Med Princ Pract. 2016;25 Suppl 2:73-5. doi: 10.1159/000443502. Epub 2015 Dec 21. No abstract available.

12.

Reply to A. Oguz et al.

O'Sullivan CC, Holmes E, Campbell C, Bradbury I, Zujewski JA, Gelber RD.

J Clin Oncol. 2016 Feb 20;34(6):640-1. doi: 10.1200/JCO.2015.65.1034. Epub 2015 Dec 7. No abstract available.

PMID:
26644531
13.

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA.

J Clin Oncol. 2016 Apr 1;34(10):1034-42. doi: 10.1200/JCO.2015.62.1797. Epub 2015 Nov 23. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):356.

14.

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

O'Sullivan CC, Bradbury I, Campbell C, Spielmann M, Perez EA, Joensuu H, Costantino JP, Delaloge S, Rastogi P, Zardavas D, Ballman KV, Holmes E, de Azambuja E, Piccart-Gebhart M, Zujewski JA, Gelber RD.

J Clin Oncol. 2015 Aug 20;33(24):2600-8. doi: 10.1200/JCO.2015.60.8620. Epub 2015 Jun 22.

15.

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N.

J Clin Oncol. 2014 Nov 20;32(33):3744-52. doi: 10.1200/JCO.2014.55.5730. Epub 2014 Oct 20.

16.

Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.

Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC.

J Natl Cancer Inst. 2014 May 19;106(6):dju089. doi: 10.1093/jnci/dju089. Print 2014 Jun.

17.

Inflammatory breast cancer: yet another risk of the obesity epidemic?

Amiri-Kordestani L, Kamangar F, Zujewski JA.

J Natl Cancer Inst. 2013 Sep 18;105(18):1340-2. doi: 10.1093/jnci/djt236. No abstract available.

PMID:
24046389
18.

A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints.

Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M; BIG-NABCG collaboration.

Lancet Oncol. 2012 Jun;13(6):e240-8. doi: 10.1016/S1470-2045(11)70378-3.

PMID:
22652232
19.

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF; International Ki-67 in Breast Cancer Working Group.

J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64. doi: 10.1093/jnci/djr393. Epub 2011 Sep 29.

20.

Triple negative breast cancer: breast cancer research in evolution.

Eng-Wong J, Hunsberger S, Zujewski JA.

Breast Dis. 2010;32(1-2):1-4. doi: 10.3233/BD-2010-0314. No abstract available.

PMID:
21778576
21.

Ductal carcinoma in situ: trends in treatment over time in the US.

Zujewski JA, Harlan LC, Morrell DM, Stevens JL.

Breast Cancer Res Treat. 2011 May;127(1):251-7. doi: 10.1007/s10549-010-1198-z. Epub 2010 Oct 8.

PMID:
20931276
22.

Breast cancer in men in the United States: a population-based study of diagnosis, treatment, and survival.

Harlan LC, Zujewski JA, Goodman MT, Stevens JL.

Cancer. 2010 Aug 1;116(15):3558-68. doi: 10.1002/cncr.25153.

23.

Multidisciplinary meeting on male breast cancer: summary and research recommendations.

Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J, Cutuli B, Pruneri G, McCaskill-Stevens W, Gralow J, Hortobagyi G, Cardoso F.

J Clin Oncol. 2010 Apr 20;28(12):2114-22. doi: 10.1200/JCO.2009.25.5729. Epub 2010 Mar 22.

24.

Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer.

Korde LA, Lusa L, McShane L, Lebowitz PF, Lukes L, Camphausen K, Parker JS, Swain SM, Hunter K, Zujewski JA.

Breast Cancer Res Treat. 2010 Feb;119(3):685-99. doi: 10.1007/s10549-009-0651-3.

25.

Recruitment to a physical activity intervention study in women at increased risk of breast cancer.

Korde LA, Micheli A, Smith AW, Venzon D, Prindiville SA, Drinkard B, Sebring N, Smith MD, Zujewski JA, Eng-Wong J.

BMC Med Res Methodol. 2009 Apr 27;9:27. doi: 10.1186/1471-2288-9-27.

26.

Recommendations for collection and handling of specimens from group breast cancer clinical trials.

Leyland-Jones BR, Ambrosone CB, Bartlett J, Ellis MJ, Enos RA, Raji A, Pins MR, Zujewski JA, Hewitt SM, Forbes JF, Abramovitz M, Braga S, Cardoso F, Harbeck N, Denkert C, Jewell SD; Breast International Group; Cooperative Groups of the Breast Cancer Intergroup of North America (TBCI); American College of Surgeons Oncology Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; National Cancer Institute of Canada Clinical Trials Group; Southwest Oncology Group; National Surgical Adjuvant Breast and Bowel Project; Radiation Oncology Group; Gynecologic Oncology Group; Children's Oncology Group.

J Clin Oncol. 2008 Dec 1;26(34):5638-44. doi: 10.1200/JCO.2007.15.1712. Epub 2008 Oct 27.

27.

Trial assessing individualized options for treatment for breast cancer: the TAILORx trial.

Zujewski JA, Kamin L.

Future Oncol. 2008 Oct;4(5):603-10. doi: 10.2217/14796694.4.5.603.

PMID:
18922117
28.

Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer.

Eng-Wong J, Orzano-Birgani J, Chow CK, Venzon D, Yao J, Galbo CE, Zujewski JA, Prindiville S.

Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1696-701. doi: 10.1158/1055-9965.EPI-07-2752. Epub 2008 Jun 26.

29.

Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions.

Gralow JR, Zujewski JA, Winer E.

J Clin Oncol. 2008 Feb 10;26(5):696-7. doi: 10.1200/JCO.2007.15.9459. Review. No abstract available.

PMID:
18258975
30.

Current NCI-sponsored Cooperative Group trials of endocrine therapies in breast cancer.

Eng-Wong J, Zujewski JA.

Cancer. 2008 Feb 1;112(3 Suppl):723-729. doi: 10.1002/cncr.23188.

31.

Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.

Come SE, Buzdar AU, Ingle JN, Johnston SRD, Brodie AM, Coombes RC, Miller WR, Pritchard KI, Winer EP, Zujewski JA, Goss PE.

Cancer. 2008 Feb 1;112(3 Suppl):673-678. doi: 10.1002/cncr.23194.

32.

Workshop on imaging science development for cancer prevention and preemption.

Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A; Workshop Program Committee.

Cancer Biomark. 2007;3(1):1-33.

PMID:
17655039
33.

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.

Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA.

J Clin Oncol. 2007 May 20;25(15):2127-32.

PMID:
17513820
34.

Proposal for the use of progression-free survival in unblinded randomized trials.

Freidlin B, Korn EL, Hunsberger S, Gray R, Saxman S, Zujewski JA.

J Clin Oncol. 2007 May 20;25(15):2122-6.

PMID:
17513819
35.

The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology.

Rapkiewicz A, Espina V, Zujewski JA, Lebowitz PF, Filie A, Wulfkuhle J, Camphausen K, Petricoin EF 3rd, Liotta LA, Abati A.

Cancer. 2007 Jun 25;111(3):173-84.

36.

What breast-cancer survivors can expect.

Zujewski JA.

Newsweek. 2007 Apr 2;149(14):10-1. No abstract available.

PMID:
19178104
37.

CNS metastasis: an old problem in a new guise.

Aragon-Ching JB, Zujewski JA.

Clin Cancer Res. 2007 Mar 15;13(6):1644-7. Review.

38.

Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer.

Faupel-Badger JM, Prindiville SA, Venzon D, Vonderhaar BK, Zujewski JA, Eng-Wong J.

Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1153-8.

39.

Raloxifene and its role in breast cancer prevention.

Eng-Wong J, Zujewski JA.

Expert Rev Anticancer Ther. 2004 Aug;4(4):523-32. Review.

PMID:
15270657
40.
41.

A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancer.

Zujewski JA, Eng-Wong J, O'Shaughnessy J, Venzon D, Chow C, Danforth D, Kohler DR, Cusack G, Riseberg D, Cowan KH.

Breast Cancer Res Treat. 2003 Sep;81(1):41-51.

PMID:
14531496
42.

Docetaxel-related skin, nail, and vascular toxicity.

Leonard GD, Zujewski JA.

Ann Pharmacother. 2003 Jan;37(1):148. No abstract available.

PMID:
12564432
43.

"Build quality in"--HER2 testing in the real world.

Zujewski JA.

J Natl Cancer Inst. 2002 Jun 5;94(11):788-9. No abstract available.

PMID:
12048261
44.

Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients.

Cowan KH, Moscow JA, Huang H, Zujewski JA, O'Shaughnessy J, Sorrentino B, Hines K, Carter C, Schneider E, Cusack G, Noone M, Dunbar C, Steinberg S, Wilson W, Goldspiel B, Read EJ, Leitman SF, McDonagh K, Chow C, Abati A, Chiang Y, Chang YN, Gottesman MM, Pastan I, Nienhuis A.

Clin Cancer Res. 1999 Jul;5(7):1619-28.

45.

Deficient DNA repair capacity, a predisposing factor in breast cancer.

Parshad R, Price FM, Bohr VA, Cowans KH, Zujewski JA, Sanford KK.

Br J Cancer. 1996 Jul;74(1):1-5.

Supplemental Content

Loading ...
Support Center